nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.08.2008 | Original Article

Comparison between ⁶⁸Ga-DOTA-NOC and ¹⁸F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

verfasst von: Valentina Ambrosini, Paola Tomassetti, Paolo Castellucci, Davide Campana, Giancarlo Montini, Domenico Rubello, Cristina Nanni, Anna Rizzello, Roberto Franchi, Stefano Fanti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

¹⁸F-FDG positron emission tomography (PET) value for the assessment of neuro-endocrine tumours (NET) is limited. Preliminary studies indicate that ¹⁸F-DOPA and ⁶⁸Ga-DOTA-NOC are more accurate for disease assessment and ⁶⁸Ga-DOTA peptides provide additional data on receptor status that are crucial for targeted radionuclide therapy. At present, there are no comparative studies investigating their role in NET.

Aim

The aim of this study was to compare ⁶⁸Ga-DOTA-NOC and ¹⁸F-DOPA for the evaluation of gastro-entero-pancreatic and lung neuro-endocrine tumours.

Materials and methods

Thirteen patients with biopsy-proven NET (gastro-entero-pancreatic or pulmonary) were prospectively enrolled and scheduled for ¹⁸F-DOPA and ⁶⁸Ga-DOTA-NOC PET. PET results obtained with both tracers were compared with each other, with other conventional diagnostic procedures (CT, ultrasound) and with follow-up (clinical, imaging).

Results

The most common primary tumour site was the pancreas (8/13) followed by the ileum (2/13), the lung (2/13) and the duodenum (1/13). The carcinoma was well differentiated in 10/13 and poorly differentiated in 3/13 cases. ⁶⁸Ga-DOTA-NOC PET was positive, showing at least one lesion, in 13/13 cases while ¹⁸F-DOPA PET was positive in 9/13. On a lesions basis, ⁶⁸Ga-DOTA-NOC identified more lesions than ¹⁸F-DOPA (71 vs 45), especially at liver, lung and lymph node level. ⁶⁸Ga-DOTA-NOC correctly identified the primary site in six of eight non-operated cases (in five cases, the primary was surgically removed before PET), while ¹⁸F-DOPA identified the primary only in two of eight cases.

Conclusions

Although the patients studied are few and heterogeneous, our data show that ⁶⁸Ga-DOTA-NOC is accurate for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours in either the primary or metastatic site and that it offers several advantages over ¹⁸F-DOPA.

Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128(6):1717–51.PubMedCrossRef

Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934–59.PubMedCrossRef

Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004;53(4):549–53.PubMedCrossRef

Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80(Suppl 1):3–7.PubMedCrossRef

Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, et al. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005;37(12):722–8.PubMedCrossRef

Papotti M, Kuma U, Volante M, Pecchiono C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol 2001;54:641–9.CrossRef

Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto M, Funahashi H. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 2002;32(8):690–4.PubMedCrossRef

Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440(5):461–75.PubMedCrossRef

Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21(1):69–85. Mar.PubMedCrossRef

10.

Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. UKNETwork for neuroendocrine tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 05;54(Suppl 4):iv1–16. Jun.CrossRef

11.

Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15–27.PubMedCrossRef

12.

Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging 2004;29:696–702.PubMedCrossRef

13.

Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006;47:1455–62.PubMed

14.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. ⁶⁸Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508–18. Apr.PubMedCrossRef

15.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617–26. Oct.PubMedCrossRef

16.

Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:79–83.PubMedCrossRef

17.

Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body ¹⁸F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220(2):373–80.PubMed

18.

Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007;451(Suppl 1):S9–27. Aug.PubMedCrossRef

19.

Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21(1):15–31. Mar.PubMedCrossRef

20.

Meyer GJ, Maecke H, Schuhmacher J, Knapp WH, Hofmann M. ⁶⁸Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31(8):1097–104. Aug.PubMedCrossRef

21.

DeVries EFJ, Luurtsema G, Brussermann M, Elsinga PH, Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6-[¹⁸F]fluoro-l-DOPA. Appl Radiat Isot 1999;51:389–94.CrossRef

22.

Ambrosini V, Tomassetti P, Rubello D, Campana D, Nanni C, Castellucci P, et al. Role of ¹⁸F-dopa PET/CT imaging in the management of patients with ¹¹¹In-pentetreotide negative GEP tumours. Nucl Med Commun 2007;28(6):473–7. Jun.PubMedCrossRef

23.

Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30(10):1338–47. Oct.PubMedCrossRef

24.

Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. ⁶⁸Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;32(6):724. Jun.PubMedCrossRef

25.

Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of ⁶⁸Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for ⁹⁰Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33(4):460–6. Apr.PubMedCrossRef

26.

Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43(5):610–6. May.PubMed

27.

Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with ¹⁷⁷Lu DOTA-TATE and ¹⁷⁷Lu DOTA-NOC. Cancer Biother Radiopharm 2007;22(3):406–16. Jun.PubMedCrossRef

28.

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30(5):781–93. May.PubMed

29.

Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. (68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72–9. [Epub ahead of print], Sep 14.PubMedCrossRef

30.

Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64(4):567–73. Apr.PubMed

31.

Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37(6):912–6.PubMed

32.

von Falck C, Boerner AR, Galanski M, Knapp WH. Neuroendocrine tumour of the mediastinum: fusion of ¹⁸F-FDG and ⁶⁸Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation. Eur J Nucl Med Mol Imaging 2007;34(5):812. May.CrossRef

33.

Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, et al. Staging of carcinoid tumours with ¹⁸F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7(9):728–34. Sep.PubMedCrossRef

34.

Orlefors H, Sundin A, Lu L, Oberg K, Langstrom B, Eriksson B, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with ¹¹C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33(1):60–5. Jan.PubMedCrossRef

Titel: Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
verfasst von: Valentina Ambrosini
Paola Tomassetti
Paolo Castellucci
Davide Campana
Giancarlo Montini
Domenico Rubello
Cristina Nanni
Anna Rizzello
Roberto Franchi
Stefano Fanti
Publikationsdatum: 01.08.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0769-2

Springer Medizin

Abstract

Purpose

Aim

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2008

Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer

99mTc-Tetrofosmin SPECT for the detection of glioma recurrence

C. Richard Goldfard, Steven R. Parmett, Lionel S. Zuckier, Fukiat Ongseng, Maroun Karam, Jeffrey A. Cooper (eds), Nuclear Medicine Board Review: questions and answers for self assessment. (Second Edition)

Optimizing interventions for preventing uptake in the brown adipose tissue in FDG-PET

Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning

Is PET always an advantage versus planar and SPECT imaging?